Compared with placebo, the drug tafamidis (Pfizer) reduces decline in left ventricular (LV) systolic and diastolic function, suggests post hoc analysis of a randomized trial of patients with ...
Results also presented during late-breaking session at ESC Heart Failure congress 2023 ZURICH, SWITZERLAND / ACCESSWIRE / May 20, 2023 / Neurimmune announced today that primary results of its Phase 1 ...
According to new research, patisiran maintains long-term kidney function in ATTR-PN. Long-term patisiran treatment maintained stable eGFR in patients with ATTR-PN and chronic kidney disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback